Prosecution Insights
Last updated: November 12, 2026
Application No. 18/741,818

COMPOSITION FOR PURIFICATION OF BIOFLUIDS

Final Rejection §103
Filed
Jun 13, 2024
Priority
Mar 14, 2018 — CN 201810208561.9 +2 more
Examiner
PROSSER, ALISSA J
Art Unit
1619
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Beacon Medcare (Hk) Limited
OA Round
2 (Final)
16%
Grant Probability
At Risk
3-4
OA Rounds
27%
With Interview

Examiner Intelligence

Grants only 16% of cases
16%
Career Allowance Rate
79 granted / 511 resolved
-44.5% vs TC avg
Moderate +11% lift
Without
With
+11.2%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
60 currently pending
Career history
575
Total Applications
across all art units

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Applicant’s Request for Reconsideration dated October 13, 2026 is acknowledged. Claims 1 and 3-21 are pending. Claim 2 is cancelled. Claims 1, 3, 5, 7, 9, 10, 12-14 and 17-20 are currently amended. Claim 21 is new. Claims 1 and 3-21 as filed on October 13, 2026 are pending and under consideration to the extent of the elected species, e.g., the species of osmotic agent is glucose, the species of toxin-removal agent is polyethylene caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer and the species of disease or condition is kidney disease. This action is made FINAL. Withdrawn Objections / Rejections In view of the amendment of the claims, all previous claim objections are withdrawn, all previous claim rejections under 35 USC 112(a) are withdrawn, all previous claim rejections under 35 USC 112(b) are withdrawn, and all previous claim rejections under 35 USC 112(d) are withdrawn. Applicant’s arguments have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Maintained Grounds of Rejection / New Grounds of Rejection Necessitated by Amendment Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1 and 3-21 are rejected under 35 U.S.C. 103 as being unpatentable over Gauthier et al. (US 4,976,683, published December 11, 1990, of record) in view of Nolph et al. (EP 89,135, published September 21, 1983, of record); Tanida et al. “Evaluation of the micellization mechanism of an amphiphilic graft copolymer with enhanced solubility of ipriflavone,” Chemical and Pharmaceutical Bulletin 64:68-72, 2016, of record; and Meyer et al. “Uremia,” New England Journal of Medicine 357(13):1316-1325, 2007, of record. Gauthier teaches a method for peritoneal dialysis of a patient in need of such treatment comprising inter alia instilling an initial volume of an aqueous peritoneal dialysis solution composition comprising an osmotic agent, wherein the osmotic agent is present at an osmolarity that is greater than the osmolarity of the body fluids, and wherein a flux of water and solute (toxin, method for reducing a toxin, method of treating a toxin-related disease or condition) enters the composition from the body fluids (title; abstract; claims, in particular 1; paragraph bridging columns 1 and 2). The patients have inadequate kidney function (kidney disease) (column 1, lines 12-16), as required by instant claim 15 and the elected embodiment. Dialysis removes impurities, toxins and other small molecules such as urea (uremic toxin, uremia), the principle nitrogenous metabolite produced by the body (paragraph bridging columns 1 and 2; column 3, lines 3-16), as required by instant claims 8-10, 16-19. The osmolarity of the composition is about 300 to 500 mOsm/L (claims 3, 4), as required by instant claim 4. The osmotic agent is selected from the group inclusive of sugars (claim 11), as required by instant claim 5. Exemplary agents include dextrose (glucose) in an amount of 5%, where percentages are understood as w/v (paragraph bridging columns 8 and 9; column 9, lines 12-22; column 12, lines 5-28; also column 5, lines 30-43 and Table 2), as required by instant claims 6, 7 and the elected embodiment. Gauthier further teaches patients with chronic renal failure (column 1, lines 18-20). Gauthier does not teach a toxin-removal agent that is polyethylene caprolactam – polyvinyl acetate – polyethylene glycol graft copolymer as required by claims 1, 14 and the elected embodiment thereof. Gauthier does not teach at least 0.0001% to at most 4% toxin-removal agent as required by claim 3. Gauthier does not teach the toxin is reduced to at most 50%, …, or at most 5% of the amount before treatment as required by claim 11. Gauthier does not teach the toxin is reduced at least 10%, …, or at least 95% of the amount before treatment as required by claims 12, 20. Gauthier does not teach the residual toxin is at most 90%, …, or at most 5% of the amount before treatment as required by claim 13. Gauthier does not teach the weight ratio of toxin-removal agent to the osmotic agent ranges from 1:1750 to 1:4 as required by claim 21. These deficiencies are made up for in the teachings of Nolph, Tanida and Meyer. Nolph, summarized at column 4, lines 29-38 of Gauthier, teaches a peritoneal dialysis solution containing 5 to 100 g/L (0.5 to 10 % w/v) sorbents for metabolic breakdown products (toxins) such as creatinine (uremic toxin) to be removed (title; abstract; claims; page 1, lines 4-15; page 3, lines 30-34; Examples), as required by instant claim 3. See MPEP 2144.05. The solution further comprises a sufficient amount of physiological salt to be osmotically compatible and an osmotic agent such as dextrose (glucose); exemplary dialysis solutions contain either 1.5 or 4.25 wt% (broadly and reasonably interpreted as equivalent to % w/v because the solution is dilute) dextrose (abstract; claim 1; page 3, lines 7-16; page 5, lines 1-8). Nolph further exemplifies enhanced removal of creatinine; various amounts of charcoal sorbent were added to determine its effect on creatine clearance (Examples; also, page 5, lines 24-30). Tanida teaches solubilization enhancement properties of an amphipathic graft copolymer, Soluplus® (polyethylene caprolactam – polyvinyl acetate – polyethylene glycol graft copolymer as evidenced by paragraph [0103] of the instant specification), on test compounds (abstract; page 68, paragraph bridging columns; Figure 1; page 69, “Solubility Study”). Micelle formation of Soluplus® improves solubility; the calculated cmc of Soluplus® is 0.82 mg/mL (0.082 % w/v) (abstract; paragraph bridging pages 69 and 70; Figures 2, 4; page 70, rhc, full paragraph), as required by instant claim 3. Furthermore, the polymer has an inherent binding site that allows hydrogen bonding and/or van der Waals interactions with drug molecules (page 68, paragraph bridging columns). Meyer teaches treatment of uremia, which once encompassed all signs and symptoms of advanced kidney failure, is dominated by dialysis (page 1316, 1st and 3rd paragraphs). Urea is quantitatively the most important uremic solute (page 1317, rhc, full paragraph; Table 1). Dialysis is adjusted to remove about two thirds of total-body urea during each treatment (page 1318, rhc, full paragraph; Figure 1), as required by instant claims 11-13, 20. Removal of solutes can be increased by various modifications of the standard dialysis treatment (page 1318, rhc, full paragraph). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the aqueous peritoneal dialysis solution composition of Gauthier to further comprise solubilization enhancers inclusive of Soluplus® (polyethylene caprolactam – polyvinyl acetate – polyethylene glycol graft copolymer as evidenced by paragraph [0103] of the instant specification) as taught by Tanida in order to enhance the solubilization of solutes such as impurities, toxins and other small molecules such as urea for removal from the body. There would be a reasonable expectation of success because Nolph and Meyer independently teach it is known in the art to add sorbents or/and to modify dialysis treatments to increase removal of solutes. Regarding claims 3 and 21, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to include solubilization enhancers inclusive of Soluplus® in an amount in excess of 0.82 mg/mL (0.082 % w/v) as taught by Tanida because the presence of micelles improves solubility. There would be a reasonable expectation of success because Nolph teaches it is known in the art to add sorbents for enhanced metabolic breakdown product removal in amounts from 5 to 100 g/L (0.5 to 10 % w/v). Additionally or/and alternatively, it would have been prima facie obvious to optimize the amount of Soluplus® in order to optimize / maximize solute / toxin removal. It is prima facie obvious to optimize such result-effective variables within prior art conditions or through routine experimentation. See MPEP 2144.05. Regarding the weight ratio of toxin-removal agent to the osmotic agent of 1:1750 to 1:4, because Gauthier exemplifies compositions comprising 5 % w/v dextrose (glucose), the combined teachings of the prior art render obvious ratios inclusive of 0.082 : 5 ~= 1 : 61. Regarding claims 11-13 and 20, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to practice the method for peritoneal dialysis of a patient in need of such treatment of Gauthier in view of Nolph and Tanida inclusive of patients with chronic renal failure until about two thirds of total-body urea is removed as taught by Meyer because this is the standard treatment for uremia or kidney disease. Additionally or/and alternatively, it would have been prima facie obvious to optimize the method in order to optimize / maximize solute / toxin removal. See MPEP 2144.05. Response to Arguments: Claim Rejections - 35 USC § 103 Applicant’s arguments have been fully considered but they are not persuasive. Applicant states the rejection is hindsight because the applied prior art addresses different problems. Applicant concludes there is no reason to combine. This is not found persuasive because it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See In re McLaughlin, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971). While the problem Gauthier identifies may be the decay of the osmolarity gradient, Applicant is reminded that patents are relevant as prior art for all they contain. See MPEP 2123. Gauthier, as a whole, concerns peritoneal dialysis (e.g., title). The purpose of peritoneal dialysis is to replace functions normally performed by the kidneys inclusive of excretion of wastes (e.g., Gauthier, column 1, lines 18-29). Nolph also concerns peritoneal dialysis (e.g., title) and Nolph discloses the use of sorbents to enhance removal of wastes. Tanada concerns solubilization (e.g., title). Applicant’s characterization of Gauthier as not teaching or suggesting increasing solubilization of any toxin is acknowledged but is unpersuasive because the point of dialysis is to partition inter alia wastes into the dialysis solution and because dialysis is not limited to the removal of urea. Applicant states the Office Action fails to provide a reasonable expectation of success of adding a polymer to increase removal of toxins. Applicant cites to Table 1 of Nolph to support the conclusion that Nolph shows that a polymer does not increase toxin clearance. This is unpersuasive because the reasonable expectation of success requirement refers to "the likelihood of success" in combining or modifying prior art disclosures to meet the limitations of the claimed invention. See MPEP 2143.02. Nolph evidences success of sorbents, e.g., additives which absorb and sequester, in peritoneal dialysis. The citation to the polymer of Nolph misses the mark because it is understood the polymer of Nolph is a “semipermeable polymeric layer” which may optionally encapsulate the “sorbent” (e.g., Nolph, claim 6). The rejection is not predicated on modifying the semipermeable polymeric layer of the sorbent of Nolph but rather on the recognition that the polymer particles of Tanida possess the same function as the sorbent of Nolph of selectively partitioning and sequestering. Applicant’s statements that Meyer, Ash and Leroux do not fill the gaps are acknowledged but not found persuasive because. Therefore, the rejections over Gauthier are properly maintained in modified form as necessitated by Applicant’s amendments. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALISSA PROSSER whose telephone number is (571)272-5164. The examiner can normally be reached M - Th, 10 am - 6 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, DAVID BLANCHARD can be reached on (571)272-0827. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ALISSA PROSSER/ Examiner, Art Unit 1619 /BENNETT M CELSA/Primary Examiner, Art Unit 1600
Read full office action

Prosecution Timeline

Jun 13, 2024
Application Filed
Jul 14, 2026
Non-Final Rejection mailed — §103
Oct 13, 2026
Response Filed
Oct 27, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778879
Cosmetic composition comprising fermented product of Nuruk
4y 6m to grant Granted Nov 03, 2026
Patent 12778876
BIO-GEL COMPOSITION AND NAIL CARE SYSTEM
4y 5m to grant Granted Nov 03, 2026
Patent 12478570
Cosmetic Formulation
7m to grant Granted Nov 25, 2025
Patent 12390503
GINKGO BILOBA LEAVE EXTRACT CAPSULE AND PREPARATION METHOD THEREFOR
3y 12m to grant Granted Aug 19, 2025
Patent 12310358
Fighting Against Varroa Parasite in Beekeeping Using a Natural Formulation Comprising Essential Oils and Wood Vinegar
3y 1m to grant Granted May 27, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
16%
Grant Probability
27%
With Interview (+11.2%)
Moderate
PTA Risk
Based on 511 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month